How to take more effective naps: Kettering Health
March 10 is National Napping Day and Kettering Health is looking to help people maximize the effectiveness of their sleep.
Kettering Health says that ideally, to prepare for daylight savings time, one would adjust their sleep schedule by 15 to 20 minutes the week before. For those who didn't do that though, napping could help fill the gap.
'Efficiency and productivity increase significantly when you're well-rested,' said Dr. Sarah Hussain, a Sleep Medicine and Family Medicine specialist at Kettering Health, in a press release.
'If you're not getting enough sleep at night, the body will crave sleep, and you will need a nap.'
That said, it's advised that one should only take a nap if necessary, otherwise it could negatively impact the sleep schedule. So, if you got 7 to 8 hours of sleep this morning, a nap may not be the best option.
Kettering Health also says that shorter naps (10 to 20 minutes) are best and can give a burst of energy, increase alertness and help improve productivity.
The non-profit also said that napping to get through the 'afternoon slump' isn't a necessity.
Kettering Health calls it a natural thing that can be overcome by eating a lighter, healthier lunch, drinking water and stretching.
For more information on napping well, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Together Women's Health Named to Inc. 5000 List for Third Consecutive Year
DETROIT--(BUSINESS WIRE)--Together Women's Health (TWH) proudly announces its inclusion on the 2025 Inc. 5000 list for the third year in a row. This honor places Together Women's Health among the most dynamic businesses in America across all industries. Together Women's Health is a women's health-focused management service organization, committed to partnering with leading physicians to build a premier network of women's health services in the U.S. TWH's affiliate network consists of 20 practices with nearly 200 providers delivering women's health services at 57 locations throughout Michigan, Illinois, Alabama, Colorado, Mississippi, Missouri, Georgia, Tennessee and Kentucky. Being named to the Inc. 5000 list for the third year in a row is a tremendous honor and a testament to the extraordinary network of women's healthcare providers who serve patients with excellence every day across the country Share The Inc. 5000 ranking celebrates companies that have achieved rapid revenue growth while demonstrating resilience, innovation, and leadership in their fields. Together Women's Health's recognition highlights the organization's commitment to advancing women's healthcare through strategic partnerships with top physicians, investment in clinical and operational excellence, and a patient-first approach to care. 'Being named to the Inc. 5000 list for the third year in a row is a tremendous honor and a testament to the extraordinary network of women's healthcare providers who serve patients with excellence every day across the country,' said Anthony Ahee, Founder and CEO of Together Women's Health. 'This recognition also reflects the dedication of our incredible team, whose passion for elevating and innovating women's health is making a real difference in the lives of the patients and communities we serve.' Together Women's Health is a growing network of leading women's healthcare practices committed to delivering exceptional, individualized care for women at every stage of life. The organization partners with leading physicians to build a premier network of women's health services in the U.S.—from routine gynecologic and obstetric care, breast health, advanced gynecologic procedures, menopause management, urogynecology, maternal fetal medicine, and more. With a focus on clinical and operational excellence, innovation, and compassionate care, Together Women's Health empowers providers to thrive while elevating the patient experience. The recognition on the 2025 Inc. 5000 list follows a year of significant milestones, including expanding into new states, adding maternal-fetal medicine expertise, and opening an Imaging Center dedicated to breast health. To learn more about a partnership with Together Women's Health, visit or contact us at partner@ About Together Women's Health Headquartered in Detroit, MI, Together Women's Health ('TWH') is a women's health management services organization committed to partnering with leading physicians to build a premier network of obstetricians and gynecologists. TWH, recently named on the Inc. 5000 list of fastest growing companies in America, supports its affiliated practices and physician partners throughout multiple states with strategic guidance, administrative resources (including revenue cycle management, marketing, human resources, finance, accounting, and IT), operational expertise and capital, thereby allowing physicians to focus on clinical excellence and serving their communities. TWH is building a network of top clinicians in a physician-led culture. For more information about Together Women's Health, please visit About Shore Capital Partners Shore Capital, a Chicago-based private equity firm with offices in Nashville, is an investor in lower middle market companies in the Healthcare, Food and Beverage, Business Services, Industrial, and Real Estate industries. Shore's strategy is to support management partners to grow faster with less risk through access to capital, world-class board and operational resources, and unmatched networking, development, and shared learnings across the portfolio. From 2020-2024, Shore received recognition from Inc Magazine as a 5x Top Founder Friendly Investor and by Pitchbook Research for leading U.S. Private Equity deal volume for the past 10 years, from 2015-2024. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant potential to grow through industry consolidation and organic growth to generate value for shareholders. Shore has approximately $13 billion of assets under management and in additional investment platforms to which it provides business and operational consulting services. To learn more about Shore Capital Partners, please visit
Business Wire
16 hours ago
- Business Wire
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced results from a long-term data integration of tralesinidase alfa enzyme replacement therapy (TA-ERT) clinical program in patients with Sanfilippo Syndrome Type B (MPS IIIB). Spruce integrated and evaluated group-level efficacy data for cerebral spinal fluid heparan-sulfate non-reducing end (CSF HS-NRE), cortical grey matter volume (CGMV), and Bayley-III Cognitive Raw Score (BSID-C), the cognitive subscale of the Bayley Scales of Infant and Toddler Development - Third Edition (Bayley-III), as well as safety data over a five-year period from clinical studies 201, 202, and 401. Data from treated patients (n=22) in the studies 201, 202, and 401 was compared with data from untreated patients with MPS IIIB in natural history studies 901 and 902. 'These data demonstrate a rapid, profound, and durable effect of ICV-administered TA-ERT on normalizing CSF HS-NRE, the pathogenic factor leading to neurodegeneration, and in stabilizing CGMV and cognitive function, relative to the declines observed in untreated children with Sanfilippo Syndrome Type B (MPS IIIB) in the natural history studies,' said Paul Harmatz, M.D., Principal Investigator in studies 901, 201, and 202 and Professor in Residence, Department of Pediatrics, University of California, San Francisco (UCSF) and UCSF Benioff Children's Hospital Oakland. 'This is an important development toward relief for children and families whose lives are impacted by this devastating condition.' 'Convincing positive outcomes have been experienced by families who resoundingly state that the benefits of TA-ERT outweigh risks in their real-world experiences,' said Cara O'Neill, M.D., FAAP, Co-Founder and Chief Science Officer of Cure Sanfilippo Foundation. 'Biomarker data, along with promising clinical outcomes, are significant and meaningful from the perspective of the patient community. Currently, there is no U.S. FDA-approved therapy for the treatment of MPS IIIB, and disease management consists of limited palliative care. We are eager to see TA-ERT advance under the accelerated approval pathway.' Cerebral Spinal Fluid Heparan-Sulfate Non-Reducing End (CSF HS-NRE) Integrated group-level data from clinical studies 201, 202, and 401 demonstrate that TA-ERT therapy significantly reduced to normal or near normal CSF HS-NRE levels over a five-year period (Figure 1). At 240 weeks, CSF HS-NRE decreased 91.5 ng/mL from baseline (95% CI: -102.10, -80.90; p<0.0001). Most participants experienced normalization of CSF HS-NRE levels eight weeks after initiating therapy. In a 2024 meeting with the U.S. Food and Drug Administration (FDA), the FDA confirmed that CSF HS-NRE is a surrogate biomarker reasonably likely to predict clinical benefit and could serve as a basis for accelerated approval. Cognitive Function In untreated patients with MPS IIIB, cognitive function peaks at around four years of age and then declines over time. In contrast, children with established disease treated with TA-ERT experienced stable cognitive function over time (Figure 2). Untreated children in the natural history studies showed a decline in cognition beginning at approximately five years of age that progressively worsened over time, while cognition in the TA-ERT treated group remained stable. Using a model-based approach, the mean (95% CI) BSID-C over six to 10 years of age was significantly higher in patients treated with TA-ERT, relative to untreated, age-matched children, with differences evident at six years of age (group difference: 10.67, 95% CI: 3.23, 18.11; p=0.005). At 10 years of age, the difference in BSID-C scores between groups increased to 34.66 (95% CI: 24.38, 44.93; p<0.0001). Although TA-ERT treatment stabilized BSID-C scores on average, increases in BSID-C scores were more commonly observed in subjects who initiated therapy at younger ages with higher baseline cognitive function and prior to the establishment of meaningful neurodegeneration. The BSID-C is anticipated to be the primary endpoint for the post-marketing clinical trial. Cortical Grey Matter Volume (CGMV) TA-ERT therapy was also associated with stabilization of CGMV, relative to the decline in CGMV observed in untreated children due to the progressive neurodegenerative nature of MPS IIIB (Figure 3). While CGMV should increase with age in children up to five years of age, there was an average loss of ~32 mL over 48 weeks in untreated children with MPS IIIB observed in study 901. Consistent with TA-ERT's mechanism of action, decreases in CGMV were observed during the initial 24 weeks of TA-ERT treatment, likely reflecting intracellular clearance of cerebral spinal fluid heparan sulfate (CSF HS) and CSF HS-NRE. CGMV stabilized from weeks 48 to 240 with TA-ERT treatment. Safety TA-ERT therapy exposure for up to 7.3 years has demonstrated an adequate safety profile in a serious and fatal disease for which no treatment is currently available. The mean (SD) exposure to TA-ERT was 4.2 (2.0) years. No deaths occurred throughout study 201 and its long-term extension studies 202 and 401. The most frequent treatment-emergent adverse event (TEAE) by preferred term (reported in ≥40% of participants) was vomiting (22 [100%]), followed by pyrexia (20 [90.9%]), upper respiratory tract infection (17 [77.3%]), pleocytosis (11 [50.0%]), COVID-19 infection (10 [45.5%]), and diarrhea (9 [40.9%]). Four (18%) patients discontinued treatment, although three (14%) discontinuations were due to hydrocephalus, a known complication of MPS IIIB. Adverse events related to the ICV device were consistent with other therapies administered by the ICV route. About Sanfilippo Syndrome Type B (MPS IIIB) MPS IIIB is an ultra-rare, serious, and fatal genetic disease characterized by deficiency in N-Acetyl-Alpha-Glycosaminidase (NAGLU), an enzyme required for the catabolism of heparan sulfate (HS) in lysosomes. It is estimated that MPS IIIB affects fewer than 1:200,000 people in the United States (U.S.), but the true incidence and prevalence are difficult to ascertain because MPS IIIB is a disease currently not included in newborn screening. The accumulation of toxic levels of cerebral spinal fluid heparan sulfate in the brain is the underlying pathophysiology of MPS IIIB. Although signs and symptoms of MPS IIIB can vary amongst affected individuals, progressive neurodegeneration typically follows a predictable path to brain atrophy, cognitive and developmental impairment, hyperactivity with aggressive and destructive behavior, delayed speech, hearing loss, and motor skill deficits. Somatic manifestations include coarse facial features, hepatosplenomegaly, and gastrointestinal symptoms. The final stage of MPS IIIB is typically marked by severe dementia, loss of motor function, and seizure activity, with patients largely bed-ridden and requiring constant care, requiring feeding tubes for hydration and nutrition, and ultimately leading to death. The estimated life expectancy of individuals with MPS IIIB ranges from 15 to 19 years of age. Currently, there are no FDA-approved therapies for MPS IIIB, and management of the disease consists of limited palliative care to improve quality of life. About Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB (Sanfilippo Syndrome Type B) who lack rhNAGLU enzyme activity. TA-ERT is expected to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection. rhNAGLU typically lacks the mannose-6-phosphate residues that are essential for efficient cellular uptake via the M6P receptor pathway. As a result, the naked enzyme is poorly absorbed by cells, including neurons. To address this challenge, TA-ERT is fused to an insulin-like growth factor 2 peptide, which binds to the cation-independent mannose-6-phosphate on cell surfaces. This fusion enables the enzyme to be internalized and delivered to the lysosome, thereby enhancing its therapeutic potential for treating MPS IIIB. By restoring NAGLU enzymatic activity and promoting clearance of lysosomal heparan sulfate and heparan sulfate non-reducing end in the brain, TA-ERT therapy is expected to preserve neuronal cell health and potentially halt or slow the neurological decline and improve clinical outcomes in affected patients. TA-ERT has been evaluated in three clinical studies in participants with MPS IIIB: the interventional study 201 and extension studies 202 and 401. Twenty-two individuals with MPS IIIB have been administered TA-ERT therapy. TA-ERT has demonstrated an adequate safety profile based on integrated five years of safety data. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit and follow us on X, LinkedIn, Facebook and YouTube. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the ability to seek accelerated approval of TA-ERT for MPS IIIB based on existing clinical data. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as 'anticipate', 'will', 'potential', 'intend', 'expect' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce's business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Spruce's filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Spruce undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Yahoo
20 hours ago
- Yahoo
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the 'Company' or 'VivoSim Labs'), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. At VivoSim Labs, he will lead go-to-market strategy, partnerships, and the expansion of the Company's San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development. Market Opportunity: According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024. Services represented 53.1% of revenue vs. models at 46.9% of revenue. The United States accounted for $325M (50.8%) of the global market for liver toxicology models and services. Adoption of 3D human-relevant systems is rising, with the global in vitro liver model market growing at 5.9% CAGR from 2020 to 2024. Category Tailwinds: Biopharma sponsors are accelerating the use of non-animal new approach methodologies (NAMs). Regulatory momentum, including the FDA Modernization Act 2.0 (2022), supports validated alternatives and is catalyzing broader adoption of human-relevant in vitro models for ADME and toxicology. How AI Helps: VivoSim Labs applies AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays. By improving signal-to-noise in dose-response analyses, the platform helps project teams prioritize candidates and plan studies with greater confidence. 'VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier,' said Tony Lialin, Chief Commercial Officer, VivoSim Labs. 'We will scale a high-touch, consultative service from our San Diego lab so pharma and biopharma teams get decision-ready toxicology insights that aim to streamline pre-IND decision-making and reduce late-stage surprises.' 'Tony has a rare track record of turning disruptive science into durable commercial engines,' said Keith Murphy, Executive Chairman, VivoSim Labs. 'As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need.' About VivoSim Labs VivoSim Labs, Inc. ("VivoSim" and the 'Company'), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration ('FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit Forward-Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding expansion of the Company's San Diego-based services; the potential for the Company's organ-specific 3D models and AI-driven analytics to deliver decision-ready insights earlier in development; the market opportunity and market size of gastrointestinal in-vitro models and toxicology services; and the ability of the Company's services to improve signal-to-noise in dose-response calls or help project teams prioritize candidates and studies with greater confidence. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. ContactInvestor Relationsinfo@ Labs, in to access your portfolio
